XML 26 R13.htm IDEA: XBRL DOCUMENT v3.7.0.1
Marketable Securities
 3 Months Ended
Mar. 31, 2017
Cash and Cash Equivalents [Abstract]  
Marketable Securities
Marketable Securities
A summary of the Company’s cash, cash equivalents and marketable securities is shown below:
 
Amortized Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Fair Value
 
(in thousands)
As of March 31, 2017
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
985,818

 
$
—

 
$
—

 
$
985,818

Commercial paper
6,834

 
—

 
—

 
6,834

Corporate debt securities
11,027

 
—

 
—

 
11,027

Total cash and cash equivalents
$
1,003,679

 
$
—

 
$
—

 
$
1,003,679

Marketable securities:
 
 
 
 
 
 
 
Corporate equity securities
43,213

 
26,159

 
—

 
69,372

Commercial paper (matures within 1 year)
132,640

 
1

 
(91
)
 
132,550

Corporate debt securities (matures within 1 year)
180,465

 
3

 
(143
)
 
180,325

Corporate debt securities (matures after 1 year)
$
22,882

 
$
—

 
$
(26
)
 
$
22,856

Total marketable securities
$
379,200

 
$
26,163

 
$
(260
)
 
$
405,103

Total cash, cash equivalents and marketable securities
$
1,382,879

 
$
26,163

 
$
(260
)
 
$
1,408,782

 
 
 
 
 
 
 
 
As of December 31, 2016
 
 
 
 
 
 
 
Cash and cash equivalents:
 
 
 
 
 
 
 
Cash and money market funds
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Total cash and cash equivalents
$
1,183,945

 
$
—

 
$
—

 
$
1,183,945

Marketable securities:
 
 
 
 
 
 
 
Government-sponsored enterprise securities (matures within 1 year)
$
15,506

 
$
2

 
$
—

 
$
15,508

Corporate equity securities
43,213

 
21,347

 
—

 
64,560

Commercial paper (matures within 1 year)
59,331

 
73

 
—

 
59,404

Corporate debt securities (matures within 1 year)
111,225

 
—

 
(85
)
 
111,140

Total marketable securities
$
229,275

 
$
21,422

 
$
(85
)
 
$
250,612

Total cash, cash equivalents and marketable securities
$
1,413,220

 
$
21,422

 
$
(85
)
 
$
1,434,557


The Company has a limited number of marketable securities in insignificant loss positions as of March 31, 2017, which the Company does not intend to sell and has concluded it will not be required to sell before recovery of the amortized costs for the investment at maturity. There were no charges recorded for other-than-temporary declines in fair value of marketable securities nor gross realized gains or losses recognized in the three months ended March 31, 2017 and 2016.